loading
Champions Oncology Inc stock is currently priced at $4.81, with a 24-hour trading volume of 170. It has seen a +1.69% increased in the last 24 hours and a -4.37% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.75 pivot point. If it approaches the $4.85 resistance level, significant changes may occur.
Previous Close:
$4.73
Open:
$4.67
24h Volume:
170
Market Cap:
$64.30M
Revenue:
$49.98M
Net Income/Loss:
$-9.64M
P/E Ratio:
-8.5709
EPS:
-0.5612
Net Cash Flow:
$-4.86M
1W Performance:
-0.41%
1M Performance:
-4.37%
6M Performance:
-12.07%
1Y Performance:
+5.48%
1D Range:
Value
$4.67
$4.67
52W Range:
Value
$4.51
$7.32

Champions Oncology Inc Stock (CSBR) Company Profile

Name
Name
Champions Oncology Inc
Name
Phone
201 808 8400
Name
Address
One University Plaza, Suite 307, Hackensack, NJ
Name
Employee
230
Name
Twitter
@ChampsOnco
Name
Next Earnings Date
2024-03-14
Name
Latest SEC Filings
Name
CSBR's Discussions on Twitter

Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-18-19 Initiated The Benchmark Company Speculative Buy

Champions Oncology Inc Stock (CSBR) Financials Data

Champions Oncology Inc (CSBR) Revenue 2024

CSBR reported a revenue (TTM) of $49.98 million for the quarter ending October 31, 2023, a -7.61% decline year-over-year.
loading

Champions Oncology Inc (CSBR) Net Income 2024

CSBR net income (TTM) was -$9.64 million for the quarter ending October 31, 2023, a -9,023% decrease year-over-year.
loading

Champions Oncology Inc (CSBR) Cash Flow 2024

CSBR recorded a free cash flow (TTM) of -$4.86 million for the quarter ending October 31, 2023, a -182.66% decrease year-over-year.
loading

Champions Oncology Inc (CSBR) Earnings per Share 2024

CSBR earnings per share (TTM) was -$0.71 for the quarter ending October 31, 2023, a -59,067% decline year-over-year.
loading

Champions Oncology Inc Stock (CSBR) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mendelson Daniel Newman
Director
Jan 11 '24
Buy
6.27
2,000
12,540
197,625
Mendelson Daniel Newman
Director
Jan 10 '24
Buy
6.31
2,944
18,577
195,625
Mendelson Daniel Newman
Director
Jan 09 '24
Buy
6.25
3,000
18,750
192,681
Mendelson Daniel Newman
Director
Jan 08 '24
Buy
6.15
1,000
6,150
189,681
Mendelson Daniel Newman
Director
Jan 05 '24
Buy
6.09
2,000
12,180
188,681
Mendelson Daniel Newman
Director
Jan 04 '24
Buy
6.12
3,000
18,360
186,681
Mendelson Daniel Newman
Director
Jan 03 '24
Buy
5.83
500
2,915
183,681
Mendelson Daniel Newman
Director
Dec 21 '23
Buy
4.92
2,500
12,300
183,181
Mendelson Daniel Newman
Director
Dec 20 '23
Buy
4.82
2,100
10,122
180,681
Mendelson Daniel Newman
Director
Dec 19 '23
Buy
4.75
5,000
23,750
178,581
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
$76.67
price down icon 0.43%
$150.05
price down icon 0.77%
$29.71
price up icon 0.37%
$171.57
price up icon 0.21%
$369.61
price down icon 1.76%
$91.89
price down icon 1.04%
Cap:     |  Volume (24h):